1268. Deputy James Lawless asked the Minister for Health if his attention has been drawn to the UK’s competition and markets authority decision to investigate the manufacturers of the medicine Remicade as a result of the latter’s alleged abuse of a dominant market position arising from its use of an anti-competitive discount scheme intended, it is alleged, to prevent the use of more affordable biosimilar medicines; if his attention has been further drawn to similar practices in the market in Ireland; his views on whether a similar investigation is required in Ireland; and if he will make a statement on the matter. [27675/17]

Summary

1268. Deputy James Lawless asked the Minister for Health if his attention has been drawn to the UK’s competition and markets authority decision to investigate the manufacturers of the medicine Remicade as a result of the latter’s alleged abuse of a dominant market position arising from its use of an anti-competitive discount scheme intended, it is alleged, to prevent the use of more affordable biosimilar medicines; if his attention has been further drawn to similar practices in the market in Ireland; his views on whether a similar investigation is required in Ireland; and if he will make a statement on the matter. [27675/17]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Competition and Consumer Protection Commission

  xml · EN · 20 June 2017

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.